Wikisage, the free encyclopedia of the second generation, is digital heritage
Brexanolone: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
*3α-hydroxy-5α-pregnan-20-one | *3α-hydroxy-5α-pregnan-20-one | ||
*allopregnanolone | *allopregnanolone | ||
On | On March 19th FDA approved | ||
''Zulresso'' i.v. for depression post partum <ref>https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm</ref> or <ref>https://www.nytimes.com/2019/03/19/health/postpartum-depression-.html?smid=nytcore-ios-share</ref> | ''Zulresso'' i.v. for depression post partum <ref>https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm</ref> or <ref>https://www.nytimes.com/2019/03/19/health/postpartum-depression-.html?smid=nytcore-ios-share</ref> | ||
{{refs}} | |||
{{Wikidata|Q28487680}} | {{Wikidata|Q28487680}} | ||
[[Category:GABAA receptor positive allosteric modulators]] | |||
